The beneficial effect of dipeptidyl peptidase-4 inhibition on diet-induced extra-pancreatic effects, especially on liver tissue remains poorly understood. Thus, we made the experimental designs as follows; five-week-old male ob/ob mice, which develop type 2 diabetic mellitus and
nonalcoholic fatty liver disease by taking a high-
carbohydrate diet (HCD), were divided into a group in which a HCD was given for 8 weeks as control, and another in which a HCD added with 0.0018%
sitagliptin was given for 8 weeks. Hepatic steatosis was seen in all mice, but the mean grade of steatosis in the
sitagliptin-administrated mice was significantly decreased. The
acetyl-CoA concentrations were lower in
sitagliptin-administrated mice, although the differences were not significant. However, the
malonyl-CoA concentrations were significantly lower in
sitagliptin-administrated mice. The expression of
acetyl-CoA carboxylase 1 was inhibited in
sitagliptin-administrated mice, irrespective of expressions of
carbohydrate responsive
element-
binding protein (ChREBP) or
sterol regulatory element-binding protein (SREBP)-1c. In conclusion,
sitagliptin may affect the development of
nonalcoholic fatty liver disease by inhibiting the production of
malonyl-CoA and thus synthesis of
fatty acids in the liver.